Revolution Medicines, Inc. (RVMD)
Dopo ore:
| Chiusura precedente | 45,56 |
| Aperto | 46,00 |
| Denaro | 46,34 x 100 |
| Domanda | 46,47 x 400 |
| Min-Max giorno | 45,80 - 46,82 |
| Intervallo di 52 settimane | 15,44 - 48,61 |
| Volume | |
| Media Volume | 1.541.754 |
| Capitalizzazione | 7,662B |
| Beta (mensile su 5 anni) | 1,44 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,84 |
| Prossima data utili | 06 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 59,85 |
GlobeNewswireRevolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation for RMC-6291, a RASG12C(ON) Inhibitor, highlights encouraging initial tolerability, safety and differentiated anti-tumor activity Investor webcast to be held Sunday, October 22 at 12:30pm Eastern Time REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Revol
- GlobeNewswire
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m. Eastern REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company will present new clinical data for two of its RAS(ON) Inhibitors and other in
- GlobeNewswire
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers REDWOOD CITY, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, co
